Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Ipilimumab N01 in Combination With Sintilimab in the Treatment of Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07878221 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07878221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07878221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Ipilimumab N01 in Combination With Sintilimab in the Treatment of Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 20, 2026
Completion date
October 20, 2030
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric / gastroesophageal junction adenocarcinoma